Table 1 Details of ovarian tissues
From: Plectin, a novel regulator in migration, invasion and adhesion of ovarian cancer
Pos. | Age | Pathology diagnosis | TNM | Type | H-Score |
|---|---|---|---|---|---|
A1 | 42 | Mucinous adenocarcinoma | T1bN0M0 | malignant | 104.53 |
A2 | 30 | Serous papillary adenocarcinoma | T1N0M0 | malignant | 143.51 |
A3 | 40 | Serous papillary adenocarcinoma | T1N0M0 | malignant | 114.55 |
A4 | 43 | Serous papillary adenocarcinoma | T1N0M0 | malignant | 114.47 |
A5 | 60 | Serous papillary adenocarcinoma | T2N0M0 | malignant | 118.61 |
A6 | 57 | Serous papillary adenocarcinoma | T1cN0M0 | malignant | 42.19 |
A7 | 39 | Serous papillary adenocarcinoma | T1aN0M0 | malignant | 126.92 |
A8 | 53 | Serous adenocarcinoma | T1aN0M0 | malignant | 100.44 |
A9 | 39 | Serous adenocarcinoma | T1aN0M0 | malignant | 83.83 |
A10 | 48 | Endometrioid adenocarcinoma | T1N0M0 | malignant | 124.96 |
B1 | 45 | Endometrioid adenocarcinoma | T2N0M0 | malignant | 110.34 |
B2 | 70 | Transitional cell carcinoma | T1N0M0 | malignant | 132.54 |
B4 | 68 | Clear cell carcinoma | T1N0M0 | malignant | 76.52 |
B5 | 37 | Clear cell carcinoma | T1aN0M0 | malignant | 75.05 |
B6 | 48 | Mucinous adenocarcinoma | T3aN1M1 | malignant | 42.19 |
B8 | 38 | Mucinous papillary adenocarcinoma | T2bNxM0 | malignant | 63.34 |
B9 | 35 | Mucinous papillary adenocarcinoma | T3aN1M0 | malignant | 64.6 |
B10 | 34 | Mucinous adenocarcinoma | T2cN1M0 | malignant | 96.41 |
C1 | 50 | Mucinous adenocarcinoma | T3cN1M0 | malignant | 85.33 |
C4 | 38 | Serous papillary adenocarcinoma | T2bN0M0 | malignant | 119.7 |
C5 | 43 | Serous papillary adenocarcinoma | T3cN1M0 | malignant | 76.82 |
C6 | 43 | Serous papillary adenocarcinoma | T2bN1M0 | malignant | 67.34 |
C7 | 49 | Serous papillary adenocarcinoma | T2cNxM0 | malignant | 64.55 |
C8 | 59 | Serous adenocarcinoma (fibrous tissue and blood vessel) | T2N0M0 | malignant | 67.37 |
C9 | 70 | Serous adenocarcinoma | T2bN0M0 | malignant | 58.44 |
C10 | 64 | Serous papillary adenocarcinoma | T2N1M0 | malignant | 78.3 |
D1 | 51 | Serous papillary adenocarcinoma | T2N1M0 | malignant | 70.41 |
D2 | 47 | Serous papillary adenocarcinoma | T3cN1M0 | malignant | 100.4 |
D3 | 59 | Serous papillary adenocarcinoma | T3aN0M0 | malignant | 35.48 |
D4 | 49 | Serous adenocarcinoma | T3aN1M0 | malignant | 56.54 |
D5 | 76 | Serous papillary adenocarcinoma | T2cN0M0 | malignant | 26.19 |
D6 | 37 | Serous papillary adenocarcinoma | T3bN1M0 | malignant | 31.37 |
D7 | 52 | Serous papillary adenocarcinoma | T3aN0M0 | malignant | 34.54 |
D8 | 47 | Serous papillary adenocarcinoma | T3bN1M0 | malignant | 99.73 |
D9 | 48 | Serous papillary adenocarcinoma | T2bNxM0 | malignant | 111.81 |
D10 | 50 | Serous papillary adenocarcinoma | T3aN0M0 | malignant | 66.67 |
E1 | 51 | Serous adenocarcinoma | T3N1M1 | malignant | 125.85 |
E2 | 43 | Serous papillary adenocarcinoma | T3N1M0 | malignant | 44.06 |
E3 | 53 | Serous papillary adenocarcinoma | T3N0M0 | malignant | 67.07 |
E4 | 39 | Serous adenocarcinoma | T3cN1M0 | malignant | 32.56 |
E5 | 53 | Serous papillary adenocarcinoma | T3bN1M0 | malignant | 29.3 |
E6 | 48 | Serous papillary adenocarcinoma | T2N1M0 | malignant | 66.38 |
E7 | 47 | Serous papillary adenocarcinoma with necrosis | T3bN0M0 | malignant | 35.26 |
E9 | 43 | Serous papillary adenocarcinoma | T3cN1M0 | malignant | 104.67 |
E10 | 63 | Serous adenocarcinoma | T2N1M0 | malignant | 45.46 |
F1 | 56 | Serous adenocarcinoma | T2N1M0 | malignant | 52.95 |
F2 | 48 | Serous adenocarcinoma | T3aN1M0 | malignant | 73.37 |
F3 | 63 | Serous papillary adenocarcinoma | T3cN1M0 | malignant | 84.35 |
F4 | 60 | Serous papillary adenocarcinoma | T2bN0M0 | malignant | 99.03 |
F5 | 49 | Serous papillary adenocarcinoma | T3bN1M0 | malignant | 75.59 |
F6 | 63 | Serous adenocarcinoma | T2N1M1 | malignant | 61.17 |
F7 | 42 | Serous adenocarcinoma | T2bN0M0 | malignant | 99.98 |
F8 | 49 | Serous adenocarcinoma | T3cN1M0 | malignant | 83.64 |
F9 | 64 | Serous papillary adenocarcinoma | T3cN1M0 | malignant | 47.01 |
F10 | 66 | Serous adenocarcinoma | T2N1M0 | malignant | 111.3 |
G2 | 40 | Serous adenocarcinoma | T2N1M0 | malignant | 62.89 |
G3 | 46 | Serous adenocarcinoma | T2N1M0 | malignant | 79.87 |
G4 | 54 | Serous adenocarcinoma | T2N1M0 | malignant | 50.28 |
G5 | 54 | Serous papillary adenocarcinoma | T3cN0M0 | malignant | 84.05 |
G6 | 51 | Serous adenocarcinoma | T2bNxM0 | malignant | 94.33 |
G7 | 54 | Serous adenocarcinoma | T3cN1M1 | malignant | 90.05 |
G8 | 53 | Serous adenocarcinoma | T3N1M0 | malignant | 120.64 |
G9 | 40 | Endometrioid adenocarcinoma | T2N1M0 | malignant | 118.42 |
G10 | 52 | Transitional cell carcinoma | T2N1M0 | malignant | 90.11 |
H1 | 40 | Normal ovarial tissue | - | malignant | 36.78 |
H2 | 19 | Normal ovarial tissue | - | normal | 47.64 |
H3 | 18 | Normal ovarial tissue | - | normal | 19.6 |
H4 | 40 | Normal ovarial tissue | - | normal | 118.14 |
H5 | 21 | Normal ovarial tissue | - | normal | 111.52 |
H6 | 21 | Normal ovarial tissue | - | normal | 112.06 |
H7 | 18 | Normal ovarial tissue | - | normal | 60.98 |
H8 | 15 | Normal ovarial tissue | - | normal | 61.94 |
H9 | 20 | Normal ovarial tissue | - | normal | 54.58 |
H10 | 14 | Normal ovarial tissue | - | normal | 62.28 |